Specificities of Atypical Non AutoImmune Diabetes (ANAID) in the French West Indies

NCT07576374 | Not Yet Recruiting

• 1 other identifier: PAP_RIPH2_2025/09
• Study Type: observational
• Target: 118
• Locations: 1 country
• Sites: 1

Brief Summary

Genetics variants could be involved in atypical non-autoimmune diabetes revealed by ketoacidosis. The objective of this research will be to determine the relationships between the genetic variants already described in known monogenic diabetes or identified as involved in glucose metabolism and its regulation, in insulin signaling pathways or in insulin secretion itself in subjects of African and Indian ancestry with atypical forms of non autoimmune diabetes.

Conditions

Metabolic Diseases; Diabetes Mellitus (Type 2); Genetic Variation; Genetic Profile; Glucose Metabolism Disorders

Keywords

Genetic diagnosis; Monogenic diabetes; Exome sequencing; Pathogenic variant; Ketoacidosis; Afro-Caribbean; African and Indian ancestry

Outcome Measures

Primary Outcomes (1)

• known pathogenic mutations described in monogenic diabetes of the MODY type

  pourcentage

  At inclusion

Secondary Outcomes (4)

• new pathogenic mutations identified in genes involved in glucose metabolism and its regulation,

  At inclusion

• genetic mutations.

  At inclusion

• association between clinical and biological data and DNAI

  At inclusion

• comparing the genetic data found in African and Indian ancestry population

  At inclusion

Study Arms (1)

case

subjects of African and Indian ancestry with atypical forms of non autoimmune diabetes.

Eligibility Criteria

• Age: 18 Years - 47 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

subjects of African and Indian ancestry with atypical forms of non autoimmune diabetes.

You may qualify if:

• Phenotypic criteria :
• Subjects from Indian or African Ancestry self-declared
• Age criteria at diagnosis:
• Early onset of diabetes: patient aged between 18 and 47 years at the time of diagnosis of diabetes Clinical criteria: at least 2 criteria Labeled type 2 diabetic
• Patient hospitalized for:
• Ketoacid decompensation Significant weight loss (more than 10% in less than 6 months) without obvious etiology Lipodystrophic / lipoatrophic appearance Presence of an associated myopathy or deafness Presence of early inaugural nephropathy or within 3 years after diagnosis Presence of early inaugural heart disease or within 3 years after diagnosis Poor response to non-insulin treatments despite good adherence
• Biological criteria:
• Absent T1D autoantibodies:
• Anti-islet antibodies (ICA) Anti-IA2 antibodies Anti-insulin antibodies Anti-ZnT8 antibodies Anti-GAD antibodies
• Other criteria:
• Informed consent signed by the patient

You may not qualify if:

• Type 1 diabetes (T1D) Presence of T1D antibodies Secondary diabetes (pancreas diseases, endocrine diseases, drug intake, infection) Other associated autoimmune pathologies Pregnancy Refusal to participate

Sponsors & Collaborators

• Centre Hospitalier Universitaire de la Guadeloupe: lead

Study Sites (1)

Centre Hospitalier Universitaire de la Guadeloupe

Les Abymes, Guadeloupe, 97159, Guadeloupe

Location

Biospecimen

Retention: SAMPLES WITH DNA

urinairy samples

MeSH Terms

Conditions

Metabolic Diseases; Diabetes Mellitus, Type 2; Glucose Metabolism Disorders; Ketosis

Condition Hierarchy (Ancestors)

Nutritional and Metabolic Diseases; Diabetes Mellitus; Endocrine System Diseases; Acidosis; Acid-Base Imbalance

Study Officials

• Fritz-Line VELAYOUDOM, Doctor

  CHU de la Guadeloupe

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Fritz-Line VELAYOUDOM, Doctor

CONTACT

0590 89 13 00; fritz-line.velayoudom@chu-guadeloupe.fr

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 4, 2026
• First Posted: May 8, 2026
• Study Start (Estimated): June 1, 2026
• Primary Completion (Estimated): September 1, 2029
• Study Completion (Estimated): September 1, 2029
• Last Updated: May 8, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will not share

Locations

GU (1)